The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Subscribe To Our Newsletter & Stay Updated
